SBFM

SBFM

USD

Sunshine Biopharma Inc. Common Stock

$1.730+0.080 (4.848%)

Real-time Price

Healthcare
Drug Manufacturers - Specialty & Generic
United States

Price Chart

Loading Chart...

Key Metrics

Market Metrics
Company Fundamentals
Trading Stats

Market Metrics

Open

$1.650

High

$1.730

Low

$1.650

Volume

0.07M

Company Fundamentals

Market Cap

8.5M

Industry

Drug Manufacturers - Specialty & Generic

Country

United States

Trading Stats

Avg Volume

0.73M

Exchange

NCM

Currency

USD

52-Week Range

Low $1.169Current $1.730High $3.9

Related News

AccessWire

Sunshine Biopharma Scores a Major Regulatory Win to Market Domperidone in Canada (NASDAQ: SBFM)

FORT LAUDERDALE, FL / ACCESS Newswire / October 28, 2025 / Momentum has a way of separating the contenders from the crowd. Sunshine Biopharma is quickly establishing which side of that line it's on. After

View more
Sunshine Biopharma Scores a Major Regulatory Win to Market Domperidone in Canada (NASDAQ: SBFM)
AccessWire

Sunshine Biopharma Gains FDA-Equivalent Clearance in Canada for Domperidone to Treat Cancer-related Nausea

FORT LAUDERDALE, FL / ACCESS Newswire / October 28, 2025 / Sunshine Biopharma Inc. , a leading pharmaceutical company focused on innovative and affordable healthcare solutions,

View more
Sunshine Biopharma Gains FDA-Equivalent Clearance in Canada for Domperidone to Treat Cancer-related Nausea
AccessWire

Sunshine Biopharma is Proving That Riding Momentum is an Effective Strategy (NASDAQ:SBFM)

FORT LAUDERDALE, FL / ACCESS Newswire / October 14, 2025 / Sunshine Biopharma is quietly engineering a flywheel model for biotech. Not a flashy one that spins fast and burns energy and cash quickly. A lean

View more
Sunshine Biopharma is Proving That Riding Momentum is an Effective Strategy (NASDAQ:SBFM)
AccessWire

Sunshine Biopharma Proves Microcap Ambition Can Deliver Large-Cap Level Execution (NASDAQ: SBFM)

FORT LAUDERDALE, FL / ACCESS Newswire / October 14, 2025 / Sunshine Biopharma is the kind of company that keeps the market honest. On paper, it's small, barely a rounding error next to the giants of

View more
Sunshine Biopharma Proves Microcap Ambition Can Deliver Large-Cap Level Execution (NASDAQ: SBFM)
Analyst Upgrades

Aegis Capital Reiterates Buy on Sunshine Biopharma, Maintains $7 Price Target

Aegis Capital analyst David Bouchey reiterates Sunshine Biopharma with a Buy and maintains $7 price target.

View more
Aegis Capital Reiterates Buy on Sunshine Biopharma, Maintains $7 Price Target